Core Laboratories N.V.
Core Laboratories N.V. Fundamental Analysis
Core Laboratories N.V. (CLB) shows weak financial fundamentals with a PE ratio of 22.87, profit margin of 6.04%, and ROE of 11.94%. The company generates $0.5B in annual revenue with weak year-over-year growth of 2.76%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 42.6/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CLB's fundamental strength across five key dimensions:
Efficiency Score
WeakCLB struggles to generate sufficient returns from assets.
Valuation Score
ExcellentCLB trades at attractive valuation levels.
Growth Score
WeakCLB faces weak or negative growth trends.
Financial Health Score
ExcellentCLB maintains a strong and stable balance sheet.
Profitability Score
WeakCLB struggles to sustain strong margins.
Key Financial Metrics
Is CLB Expensive or Cheap?
P/E Ratio
CLB trades at 22.87 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, CLB's PEG of -15.55 indicates potential undervaluation.
Price to Book
The market values Core Laboratories N.V. at 2.60 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 7.42 times EBITDA. This is generally considered low.
How Well Does CLB Make Money?
Net Profit Margin
For every $100 in sales, Core Laboratories N.V. keeps $6.04 as profit after all expenses.
Operating Margin
Core operations generate 10.46 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $11.94 in profit for every $100 of shareholder equity.
ROA
Core Laboratories N.V. generates $5.33 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Core Laboratories N.V. generates limited operating cash flow of $37.85M, signaling weaker underlying cash strength.
Free Cash Flow
Core Laboratories N.V. produces free cash flow of $22.98M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.49 in free cash annually.
FCF Yield
CLB converts 3.13% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
22.87
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-15.55
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.60
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.38
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.74
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.07
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.12
vs 25 benchmark
ROA
Return on assets percentage
0.05
vs 25 benchmark
ROCE
Return on capital employed
0.11
vs 25 benchmark
How CLB Stacks Against Its Sector Peers
| Metric | CLB Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 22.87 | 19.95 | Worse (Expensive) |
| ROE | 11.94% | 963.00% | Weak |
| Net Margin | 6.04% | -48347.00% (disorted) | Weak |
| Debt/Equity | 0.74 | -0.54 (disorted) | Distorted |
| Current Ratio | 2.07 | 4.82 | Strong Liquidity |
| ROA | 5.33% | -2296.00% (disorted) | Weak |
CLB outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Core Laboratories N.V.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-25.85%
Industry Style: Cyclical, Value, Commodity
DecliningEPS CAGR
-70.88%
Industry Style: Cyclical, Value, Commodity
DecliningFCF CAGR
-40.43%
Industry Style: Cyclical, Value, Commodity
Declining